インヒビターの有無にかかわらず、血友病Aの小児におけるMim8に関する研究

基本情報

NCT ID

NCT05306418

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

70

治験依頼者名

Novo Nordisk A/S

概要

This study is looking at how Mim8 works compared to other medicines in children with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used for prevention of bleeds. Mim8 will be injected with a thin needle into the skin. The study will last for about 54-98 weeks, from screening to follow-up visit, In case the participant experiences bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor.

対象疾患

介入

依頼者（Sponsor）

実施施設 (4)